If the FDA Approves Mifepristone . . . What Happens Next?
Will Doctors Provide It? Do Women Want It?
And, What Effect Will It Have on Abortion Politics?
Tuesday, June 13, 2000
9:30am – 11:30am
Broadway Millennium Hotel, Rooms 304/305
44th and Broadway, New York City
9:30 am Registration
9:50 am Welcome/Introductions
10:00 am News from the Frontlines: The Latest on Mifepristone
What’s Happening with the Food and Drug Administration?Sandra Arnold, Vice President for Corporate Affairs at the Population Council, will report on where FDA approval of mifepristone stands today.
. . . And, Will Doctors Provide Mifepristone Once It Is Approved?
Tina Hoff, Director of Public Health Information and Communications, Kaiser Family Foundation, will present new data from an ongoing national survey of gynecologists and family practice doctors about their attitudes toward and likelihood of prescribing the drug.
10:45 am What Mifepristone Will Mean for Providers, Patients, and Abortion Politics
Ms. Hoff will moderate a discussion with leading experts on medical abortion about what happens after FDA approval:
- Eric Schaff, MD, University of Rochester School of Medicine
, will talk about how and why he – as a family practice specialist – got involved in medical abortion research and what his work says about the ways women and health care providers will respond to mifepristone;
, will discuss her research – including extensive interviews with physicians – about the day-to-day realities of providing medical abortions; and
and Editor, Journal of the American Medical Women’s Association, will reveal findings from the journal’s just-released special issue on medical abortion – including the likely impact on abortion practice and politics.
11:30 a.m. Questions and Answers